Tiziana life sciences announces initiation of clinical trial in a secondary progressive multiple sclerosis (spms) patient with nasal administration of foralumab, a fully human anti-cd3 monoclonal antibody, under an individual patient expanded access program
New york and london, may 25, 2021 (globe newswire) -- tiziana life sciences plc (nasdaq: tlsa, lse: tils) (“tiziana” or the “company”), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, is pleased to announce that the first patient with secondary progressive multiple sclerosis (spms) was dosed with nasally administered foralumab, a fully human anti-cd3 monoclonal antibody, at the brigham and women's hospital (bwh), harvard medical school, boston, ma. nasal foralumab 50 mcg (25 mcg/nostril) will be administered in 3-week cycles, with 3 times/week dosing for the first 2 weeks followed by 1 week of rest period. this first-ever clinical study in spms patients, under an individual patient expanded access ind, will continue for six months to evaluate routine safety, tolerability, and neurological behaviors. the study will also examine microglial activation, by positron emission tomography (pet), immunological and neurodegenerative markers to assess clinical responses following the treatment regimen.
TLSA Ratings Summary
TLSA Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission